STOCK TITAN

Tenax Therapeutics Inc - TENX STOCK NEWS

Welcome to our dedicated news page for Tenax Therapeutics (Ticker: TENX), a resource for investors and traders seeking the latest updates and insights on Tenax Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tenax Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tenax Therapeutics's position in the market.

Rhea-AI Summary
Tenax Therapeutics, Inc. secures global rights to levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction, expanding territory from North America to worldwide. The agreement with Orion Corporation includes improved net sales royalty rates, modified milestone provisions, and exclusion of neurological indications from Tenax's right of first negotiation for new levosimendan applications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.86%
Tags
none
-
Rhea-AI Summary
Tenax Therapeutics, Inc. announced the pricing of a public offering of 1,600,000 shares of its common stock and warrants to purchase up to 3,200,000 shares at a purchase price of $5.65 per share. The offering is expected to close soon, with the proceeds intended for general corporate purposes and working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-64.45%
Tags
offering
-
Rhea-AI Summary
Tenax Therapeutics, Inc. has announced the enrollment of the first patient in the Phase 3 LEVEL Study, a trial for the treatment of pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF). The study will involve 152 patients and is expected to produce topline data by the second half of 2025. The company has highlighted the reduced costs and time for the registration of TNX-103 due to the FDA not requiring a long-term cardiovascular outcomes trial, and the extensive patent estate for levosimendan until at least 2040.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-64.45%
Tags
clinical trial
Rhea-AI Summary
Tenax Therapeutics, Inc. has been granted a patent providing U.S. intellectual property protection until December 2040 for the use of TNX-103, TNX-102, TNX-101, and active metabolites of levosimendan in the treatment of PH-HFpEF. The patent also covers the use of levosimendan in combination with various cardiovascular drugs for improving exercise performance in PH-HFpEF patients. The new patent broadens existing IP claims, including coverage of expanded dose ranges and drug combinations. The company aims to evaluate the clinical utility of levosimendan in other areas of cardiovascular disease, with a focus on the Phase 3 LEVEL study. This patent adds significant value to the company's IP portfolio and future drug development endeavors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.31%
Tags
none
-
Rhea-AI Summary
Tenax Therapeutics, Inc. (Nasdaq: TENX) announced a 1-for-80 reverse stock split aimed at addressing Nasdaq's minimum bid price requirement. The reverse split will reduce outstanding shares from 23,862,434 to approximately 292,281, with no change to authorized shares or par value per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.79%
Tags
none
-
Rhea-AI Summary
Tenax Therapeutics, Inc. (Nasdaq: TENX) announced the appointment of Javed Butler, M.D., M.P.H, M.B.A., to the Company’s PH-HFpEF Scientific Advisory Board. Dr. Butler, a renowned clinical trialist in cardiovascular medicine, will join the distinguished SAB overseeing the development of levosimendan. This follows the FDA clearance of Tenax’s planned Phase 3 investigation of oral levosimendan in PH-HFpEF.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.29%
Tags
management
Rhea-AI Summary
Tenax Therapeutics, Inc. (Nasdaq: TENX) announces FDA clearance for Phase 3 study of TNX-103 in PH-HFpEF patients, with the first study, The LEVEL Study, set to commence in 4Q 2023. The FDA has agreed that 6MWD will be the primary endpoint for both Phase 3 studies. The Phase 3 program is designed to meet FDA's request for subject drug exposure of 300 patients for 6 months and 100 patients for 1 year. Oral levosimendan use in PH-HFpEF is protected by a USPTO granted patent until 2040. There are no FDA-approved treatments for PH-HFpEF, with an estimated prevalence of more than 2,000,000 patients in North America by 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
297.44%
Tags
clinical trial
-
Rhea-AI Summary
Tenax Therapeutics, Inc. (Nasdaq: TENX) - New U.S. patent granted for oral levosimendan (TNX-103) in the treatment of pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) until December 2040. The patent broadens Tenax’s U.S. IP protection and covers the use of oral levosimendan for the treatment of PH-HFpEF, with potential to generate billions in future estimated annual sales. TNX-103, the only drug to show statistically significant improvement in the 6-minute walk endpoint in Phase 2 HELP Study, will initiate a Phase 3 trial in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.51%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
none
Tenax Therapeutics Inc

Nasdaq:TENX

TENX Rankings

TENX Stock Data

6.98M
278.82k
0.39%
4.55%
10.09%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Morrisville

About TENX

tenax therapeutics is focused on developing and commercializing pharmaceutical products that improve outcomes for patients who require treatment for various critical care conditions. our development portfolio includes novel product candidates that have the potential to address various critical care conditions with high unmet medical need.